Manifold Bio

Manifold Bio is a transformative therapeutics company founded in 2020 with a mission to revolutionize protein therapeutics discovery through high-throughput in vivo measurement. The company's groundbreaking approach is enabled by a novel protein barcoding technology and other innovations that bridge molecular biology and compute, giving them an unprecedented advantage in engineering precision biologics. With a focus on making life-saving drugs available to patients as quickly as possible, Manifold Bio has assembled a team with unique expertise in library-guided protein engineering, DNA synthesis, sequencing, and advanced bioinformatics and machine learning. With its last investment of $40.00MSeries A investment at 13 June 2022, Manifold Bio has garnered support from a notable group of investors including Horizons Ventures, Playground Global, 50Y, Section 32, FPV Ventures, FAST — by GETTYLAB, Triatomic Capital, and Tencent. The company's headquarter is situated in the United States, and it operates within the Biotechnology, Health Care, and Pharmaceutical industries. Manifold Bio's pioneering platform and innovative approach to engineering biology position it as a promising player in the biotech sphere, attracting attention and investment from key players in the venture capital landscape.